AMAG Pharmaceuticals (AMAG) Announces FDA Approval of Feraheme
More News related to AMAG
- AMAG Pharmaceuticals, Inc. to Participate in the Lazard Capital Markets 6th Annual Healthcare Conference
- Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Incrementally Positive on CMS News
- AMAG Pharma (AMAG) Posts Q3 Loss of $1.29
- AMAG Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2009
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) said the FDA has granted marketing approval for Feraheme Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
The recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg IV injection three to eight days later. Feraheme should be administered as an undiluted IV injection delivered at a rate of up to 1 mL/sec (30 mg/sec). The recommended Feraheme dose may be readministered to patients with persistent or recurrent iron deficiency anemia.
Related Categories
FDAStocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
